23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Arcutis Biotherapeutics, Inc. › 2025-2026

Arcutis Biotherapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 305Asset managers, any item
  • 1,545Fund votes
  • June 5, 2026Meeting date

Results at a glance

Meeting of June 5, 2026: 5 items on Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 9, 2026: 5 passed (calculated).

Dissent

Significant dissent: 1 director (32.6% against).

Notable dissent: 2 directors (19.6%, 18.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 6.7%, as of September 30, 2026)

Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arcutis Biotherapeutics, Inc.

These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcutis Biotherapeutics, Inc. — official shareholder meeting results, meeting held June 5, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Patrick J. Heron 62,830,439---- 30,446,09814,868,017 67%Passed (calculated)—
Elect Director: Neha Krishnamohan 74,956,903---- 18,319,63414,868,017 80%Passed (calculated)—
Elect Director: Todd Franklin Watanabe 75,771,853---- 17,504,68414,868,017 81%Passed (calculated)—
2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 107,867,44215,748261,364 ---- 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers 88,728,2693,723,408824,860 --14,868,017 96%Passed (calculated)—

Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.

How asset managers voted at the Arcutis Biotherapeutics, Inc. 2025-2026 meeting

305 asset managers disclosed a vote on at least one Arcutis Biotherapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Neha Krishnamohan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 74,956,903WITHHELD: 18,319,634
Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Neha Krishnamohan

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Neha Krishnamohan”): 74,956,903 for, 18,319,634 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 26,182,809 for, 4,712,901 withheld, 50 abstained.

FORWITHHOLD
FOR: 26,182,809ABSTAIN: 50WITHHOLD: 4,712,901
Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,849,9970 5055,434For
State Street3,804,2130 04,442For
BlackRock3,277,0100 00For
Fidelity2,954,0460 053,100For
Prudential/PGIM2,217,7920 03,298For
OBERWEIS FUNDS00 01,211,800Withhold
American Century00 01,120,551Withhold
Charles Schwab1,012,9550 00For
TIAA870,2420 00For
FRANKLIN STRATEGIC SERIES850,0580 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)710,0000 00For
Federated Hermes689,8430 00For
Franklin Custodian Funds400,0000 00For
DRIEHAUS MUTUAL FUNDS00 0396,980Withhold
First Trust00 0351,058Withhold
Bridge Builder Trust334,4080 00For
T. Rowe Price281,4890 00For
Equitable156,3630 074,380Mixed
AMG FUNDS230,0380 00For
Jackson National147,0000 056,192Mixed
AIG/SunAmerica00 0179,784Withhold
BUFFALO FUNDS173,3060 00For
Principal Exchange-Traded Funds00 0163,367Withhold
Lincoln Financial74,8000 068,824Mixed
Allspring00 0132,842Withhold

Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).

Elect Director: Patrick J. Heron

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD
FOR: 62,830,439WITHHELD: 30,446,098
Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Patrick J. Heron

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Patrick J. Heron”): 62,830,439 for, 30,446,098 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 22,200,421 for, 8,695,256 withheld, 83 abstained.

FORWITHHOLD
FOR: 22,200,421ABSTAIN: 83WITHHOLD: 8,695,256
Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,849,9640 8355,434For
State Street7,6800 03,800,975Withhold
BlackRock3,277,0100 00For
Fidelity2,954,0460 053,100For
Prudential/PGIM2,217,7920 03,298For
OBERWEIS FUNDS00 01,211,800Withhold
American Century00 01,120,551Withhold
Charles Schwab1,012,9550 00For
TIAA870,2420 00For
FRANKLIN STRATEGIC SERIES850,0580 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)710,0000 00For
Federated Hermes689,8430 00For
Franklin Custodian Funds400,0000 00For
DRIEHAUS MUTUAL FUNDS00 0396,980Withhold
First Trust00 0351,058Withhold
Bridge Builder Trust334,4080 00For
T. Rowe Price281,4890 00For
Equitable156,3630 074,380Mixed
AMG FUNDS230,0380 00For
Jackson National147,0000 056,192Mixed
AIG/SunAmerica00 0179,784Withhold
BUFFALO FUNDS173,3060 00For
Principal Exchange-Traded Funds00 0163,367Withhold
Lincoln Financial00 0143,624Withhold
Allspring00 0132,842Withhold

Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).

Elect Director: Todd Franklin Watanabe

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 75,771,853WITHHELD: 17,504,684
Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Todd Franklin Watanabe

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Todd Franklin Watanabe”): 75,771,853 for, 17,504,684 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 26,332,327 for, 4,563,385 withheld, 48 abstained.

FORWITHHOLD
FOR: 26,332,327ABSTAIN: 48WITHHOLD: 4,563,385
Largest asset managers voting on “Election of Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their su” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,849,9990 4855,434For
State Street3,804,2130 04,442For
BlackRock3,277,0100 00For
Fidelity2,954,0460 053,100For
Prudential/PGIM2,217,7920 03,298For
OBERWEIS FUNDS00 01,211,800Withhold
American Century00 01,120,551Withhold
Charles Schwab1,012,9550 00For
TIAA870,2420 00For
FRANKLIN STRATEGIC SERIES850,0580 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)710,0000 00For
Federated Hermes689,8430 00For
Franklin Custodian Funds400,0000 00For
DRIEHAUS MUTUAL FUNDS00 0396,980Withhold
First Trust00 0351,058Withhold
Bridge Builder Trust334,4080 00For
T. Rowe Price281,4890 00For
Equitable230,7430 00For
AMG FUNDS230,0380 00For
Jackson National147,0000 056,192Mixed
AIG/SunAmerica00 0179,784Withhold
BUFFALO FUNDS173,3060 00For
Principal Exchange-Traded Funds00 0163,367Withhold
Lincoln Financial74,8000 068,824Mixed
Allspring00 0132,842Withhold

Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).

Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 88,728,269AGAINST: 3,723,408

Prior year: 84.7% for (June 12, 2025 meeting) ▲ 11.3 pts

Details: description as filed, official tally, votes by 305 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 88,728,269 for, 3,723,408 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 87 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,905,4726 30For
State Street3,808,6550 00For
BlackRock3,277,0100 00For
Fidelity3,007,1460 00For
Prudential/PGIM2,221,0900 00For
OBERWEIS FUNDS1,211,8000 00For
American Century01,120,551 00Against
Charles Schwab1,012,9550 00For
TIAA870,2420 00For
FRANKLIN STRATEGIC SERIES850,0580 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)710,0000 00For
Federated Hermes689,8430 00For
Franklin Custodian Funds400,0000 00For
DRIEHAUS MUTUAL FUNDS396,9800 00For
First Trust351,0580 00For
Bridge Builder Trust334,4080 00For
T. Rowe Price281,4890 00For
Equitable230,7430 00For
AMG FUNDS230,0380 00For
Jackson National203,1920 00For
AIG/SunAmerica179,7840 00For
BUFFALO FUNDS173,3060 00For
Principal Exchange-Traded Funds163,3670 00For
Lincoln Financial143,6240 00For
Allspring132,8420 00For

Fund voting reports, all 87 managers: 29,665,630 for, 1,218,642 against, 11,166 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 241 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
MONTANOVA CAPITAL, LLC11,785,5190 00For
Polar Capital Holdings Plc10,719,3200 00For
Frazier Life Sciences Management, L.P.9,874,5110 00For
State Street6,184,1133,852 00For
JENNISON ASSOCIATES LLC4,294,7410 00For
Rubric Capital Management LP4,151,3540 00For
BlackRock3,670,107656 00For
GEODE CAPITAL MANAGEMENT, LLC3,047,9120 00For
FRANKLIN ADVISERS INC2,270,4570 00For
OBERWEIS ASSET MANAGEMENT INC/1,365,9410 00For
Ensign Peak Advisors, Inc1,244,3870 00For
American Century01,242,708 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC1,179,4490 00For
Janus Henderson1,135,9580 00For
Candriam S.C.A.01,086,651 00Against
Federated Hermes1,059,2990 00For
Charles Schwab1,013,1360 00For
DE Shaw986,5790 00For
BAMCO INC /NY/930,0000 00For
Vanguard927,7500 00For
Nuveen900,2160 00For
Northern Trust852,0620 00For
GW&K Investment Management, LLC794,2110 00For
MPM BioImpact LLC686,6160 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND676,2000 00For

Institutional-manager reports, all 241 managers: 79,587,267 for, 2,981,555 against, 59 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 107,867,442AGAINST: 15,748

Prior year: 100.0% for (June 12, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 107,867,442 for, 15,748 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 88 asset managers below reported 30,884,596 for, 11,164 abstained.

FOR
FOR: 30,884,596ABSTAIN: 11,164
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as ” at Arcutis Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,905,4800 10For
State Street3,808,6550 00For
BlackRock3,277,0100 00For
Fidelity3,007,1460 00For
Prudential/PGIM2,221,0900 00For
OBERWEIS FUNDS1,211,8000 00For
American Century1,120,5510 00For
Charles Schwab1,012,9550 00For
TIAA870,2420 00For
FRANKLIN STRATEGIC SERIES850,0580 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)710,0000 00For
Federated Hermes689,8430 00For
Franklin Custodian Funds400,0000 00For
DRIEHAUS MUTUAL FUNDS396,9800 00For
First Trust351,0580 00For
Bridge Builder Trust334,4080 00For
T. Rowe Price281,4890 00For
Equitable230,7430 00For
AMG FUNDS230,0380 00For
Jackson National203,1920 00For
AIG/SunAmerica179,7840 00For
BUFFALO FUNDS173,3060 00For
Principal Exchange-Traded Funds163,3670 00For
Lincoln Financial143,6240 00For
Allspring132,8420 00For

Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).

Largest Arcutis Biotherapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,042,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.52%
2State Street 3.05%
3BlackRock 2.62%
4Fidelity 2.40%
5Prudential/PGIM 1.78%
6OBERWEIS FUNDS 0.97%
7American Century 0.90%
8Charles Schwab 0.81%
9TIAA 0.70%
10FRANKLIN STRATEGIC SERIES 0.68%
Institutional-manager reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1MONTANOVA CAPITAL, LLC 9.43%
2Polar Capital Holdings Plc 8.57%
3Frazier Life Sciences Management, L.P. 7.90%
4State Street 4.95%
5JENNISON ASSOCIATES LLC 3.43%
6Rubric Capital Management LP 3.32%
7BlackRock 2.94%
8GEODE CAPITAL MANAGEMENT, LLC 2.44%
9FRANKLIN ADVISERS INC 1.82%
10OBERWEIS ASSET MANAGEMENT INC/ 1.09%

Reported Arcutis Biotherapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Arcutis Biotherapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Suvretta Capital Management, LLC9,534,837 7.63%Proxy statement (DEF 14A), table as of April 8, 2026
BlackRock9,200,411 7.36%Form 13F, quarter ended March 31, 2026
Patrick J. Heron8,855,253 7.08%Proxy statement (DEF 14A), table as of April 8, 2026
Frazier Life Sciences VIII, L.P.8,785,284 7.03%Proxy statement (DEF 14A), table as of April 8, 2026
Rubric Capital Management LP8,271,577 6.62%Schedule 13G, filed February 13, 2026
Vanguard Group7,253,936 5.80%Form 13F, quarter ended March 31, 2026
State Street6,296,197 5.04%Form 13F, quarter ended March 31, 2026
PRUDENTIAL FINANCIAL INC5,302,713 4.24%Schedule 13G, filed May 8, 2026
Jennison Associates LLC4,980,770 3.98%Schedule 13G, filed May 6, 2026
Morgan Stanley4,340,239 3.47%Form 13F, quarter ended March 31, 2026

Percentages above are of 125,042,000 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Arcutis Biotherapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 305 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,545 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Arcutis Biotherapeutics (ARQT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arcutis-biotherapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.